Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer-Testis Antigen (CTA) Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SEMG2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SEMG2 ECD-Fc / His-tagged Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View SEMG2 Products |
| Gene Delivery | SEMG2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View SEMG2 Products |
| Benchmark Ab | Anti-SEMG2 Recombinant Antibody Recombinant positive control for binding and internalization assays. |
View SEMG2 Products |
| Validator | SEMG2 siRNA Set For knockdown verification and target specificity validation. |
View SEMG2 Products |
| Related Target A | SEMG1 High homology family member (78% sequence identity) required for counter-screening to prevent off-target binding. |
View SEMG1 Products |
| Related Target B | KLK3 (PSA) Primary protease responsible for SEMG2 cleavage. Crucial for microenvironment cleavage resistance assays. |
View KLK3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SEMG1 vs. SEMG2 Cross-Reactivity | Human SEMG1 and SEMG2 recombinant proteins strictly verified by mass spectrometry to guarantee sequence identity and purity |
| Proteolytic Cleavage Interference | HEK293-expressed intact SEMG2 protein available to validate antibody binding before and after KLK3 (PSA) enzymatic digestion |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog for assay calibration |
| False Positives in Screening | Target-specific validated siRNA pool included for loss-of-function validation in tumor cell lines |
Live SEMG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of Semenogelin-II (SEMG2) as a therapeutic target is gaining momentum within the oncology sector. Historically characterized as a seminal vesicle-specific protein responsible for semen coagulation, SEMG2 has been reclassified as a highly promising Cancer-Testis Antigen (CTA). Its expression profile is highly restricted in healthy tissues but aberrantly upregulated in several malignancies, including prostate cancer, lung adenocarcinoma, leukemia, and breast cancer.
As the oncology pipeline shifts from broad-spectrum immunotherapies to highly selective tumor-homing modalities, SEMG2 represents an optimal target for Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor T-cell (CAR-T) therapies, and bispecific T-cell engagers (BiTEs). The key to unlocking SEMG2's clinical potential lies in designing antibodies that can differentiate it from its highly homologous family member, SEMG1, and remain stable in the presence of prostate-specific antigen (PSA) proteolytic activity within the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech Startups, Academic Institutes | Prostate Cancer, Breast Cancer | Internalization Assay & Cleavage Stability (Requires high-purity ECD-Fc proteins) |
| CAR-T / Cell Therapy | Cell Therapy Developers | Refractory Solid Tumors, Leukemia | Target Specificity Screening (Requires SEMG1/SEMG2 counter-screening panel) |
| Monoclonal Antibodies | Translational Oncology Groups | Lung Adenocarcinoma | Epitope Mapping & Blockade Verification (Requires sequence-verified proteins) |